X
All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): BBV154
Therapeutic Area: Infections and Infectious Diseases Product Name: BBV154
Highest Development Status: Phase I Product Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 08, 2021
Details:
BBV154 (intranasal Covid-19 vaccine), preclinical testing has been completed for toxicology, immunogenicity and challenge studies. The Phase-1 trials will be conducted in Saint Louis University's Vaccine and Treatment Evaluation Unit.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): VXA-CoV2-1
Therapeutic Area: Infections and Infectious Diseases Product Name: VXA-CoV2-1
Highest Development Status: Phase I Product Type: Vaccine
Partner/Sponsor/Collaborator: Vaxart
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement October 07, 2020
Details:
The manufacturing services will be performed via Centaur Biopharmaceutical Services (Centaur), a wholly owned subsidiary of KindredBio that provides full service contract development and manufacturing services.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): BBV87
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase I Product Type: Vaccine
Partner/Sponsor/Collaborator: CEPI
Deal Size: $14.1 million Upfront Cash: Undisclosed
Deal Type: Funding May 03, 2020
Details:
CEPI will fund the consortium for vaccine manufacturing and clinical development of a 2-dose live-inactivated vaccine (BBV87) against Chikungunya. The partnering agreement will finance a multi-centre Phase 2/3 adaptive clinical trial to be conducted by IVI.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): GYROX-1
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: University of Tokyo Edge Capital
Deal Size: $7.5 million Upfront Cash: Undisclosed
Deal Type: Financing April 22, 2020
Details:
This investment enables Bugworks to complete Phase 1 studies for its GYROX series Intravenous drug candidate and advance an Oral lead towards clinical development.
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
